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MYOCARDIAL INFARCTION 
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06je&ees. This study evaluated whether increased intake of 
fish oils (eicosapentaenoic and dcrosahexaenoic acids) might 
reduce the risk of coronary heart disease. 
Background. Observational and clinical studies have suggested 
that increased intake of fish oils, as reflected in plasma levels of 
fish oils, may reduce the risk of myocardial infarction. 
Methods. A nested case-control study was conducted among the 
14,916 participants in the Physicians’ Health Stody with a sample 
of plasma before randomization. Each participant with myocar- 
dial infarction occurring during the first 5 years of follow-up was 
matched by smoking status and age with a randomly chosen 
control participant who had not developed coronary heart disease. 
Results. Mean levels of fish oils (with 95% confidence interval 
[CI] for paired differences and p values) in case and control 
The possibility of a beneficial effect of fish oils was raised by 
the observation of extremely low cardiovascular mortality in 
Greenland Eskimos, a population with an average estimated 
intake >350 g/day of whale and seal meat (l-3). High intakes 
of fish and very low rates of coronary heart disease were also 
found m Japan (4,5), where areas of higher fish intake were 
specifically shown to have lower rates of mortality for coronary 
heart disease compared with the rest of the country (6). 
Basic research identified omega t-3 (w-3) fatty acids in fish, 
represented primarily by eicosapentaenoic and docosahexae- 
noic acids, as agents affecting processes involved in coronary 
atherosclerosis (7-10). Their mechanisms of action seem to be 
related, at least in part, to eicosanoid metabolism (1,ll). 
Eicosapentaenoic acid competes with arachidonic acid as 
substrate for cyclooxygenase and lipoxygenase. In particular, 
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participants, expressed as percent of total fatty acids, were, for 
eicosapentaenoic acid, 0.26 versus 0.25 (95% CI -0.03 to 0.05, p = 
0.70) in cholesterol esters and 0.56 versus OS4 (95% CI -0.04 to 
0.09, p = 0.44) in phospholipids, and for docosahexaenoic acid, 
0.23 versus 0.24 (95% CI -0.07 to 0.04, p = 0.64) in cholesterol 
esters and 2.22 versus 2.14 (95% CI -0.10 to 0.27, p = 0.36) in 
phospholipids. Results adjusted for mJor cardiovascular risk 
factors sbc:ved 2 very similar lack of association between fish oil 
levels and the incidence of myocardial infarction. 
Conclu.sions. These results indieate no beueficial effect of 
increased fish oil consumption on the incidence of a first myocar- 
dial infarction. However, the effect of very high levels of fish oils 
could not be evaluated. 
(J Am Co11 Cmdiol 1995;25:387-94) 
- 
eicosapentaenoic acid is transformed into thromboxane A3 (a 
weak platelet aggregator and vasoconstrictor) and prostacyclin 
I, (an active inhibitor of platelet aggregation and vasodilator) 
and decreases the production of thromboxane A2 (a potent 
platelet aggregator and vasoconstrictor). This resulting de- 
crease in thrombogenicity and vascular reactivity is a plausible 
mechanism for a possible protective effect of fish oils in 
cardiovascular disease (11-13). Fish oils may also reduce the 
risk of thrombosis by increasing concentrations of plasminogen 
activator and decreasing concentratioF!q of plasminogen inhib- 
itor and fi:brinogen (14). Other potentially antiatherogenic 
actions of fish oils are reduction of plasma triglyceride levels 
(9) and blood pressure (15,16). 
A randomized trial (17) of diet in patients with a previous 
myocardial infarction found a significant reduction in all-cause 
mortality and ischemic heart disease deaths in the patients 
assigned to the fatty fish intervention group. However, it is not 
known whether the oil in the fish or some other nutrients were 
responsible for the observed benefit. Observational studies of 
fish intake and cardiovascular disease in populations free of 
coronary disease have presented conflicting results (18-24). 
The prcsmt stmiy SW carried out to investigate the asso, 
ciation between fish oi! levels in plasma cholesterol esters and 
phospholipids and the incidence of myocardial infarction in a 
cohort of apparently healthy men without a previous myocar- 
dial infarction. Because plasma levels of fatty acids are not 
avai!ab!e from previous cohort studies, the presen! study can 
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address the specific role of fish oils on the risk of cardiovascu- 
lar disease. 
Methods 
Shdy population. The study was conducted among partic- 
ipants in the Physicians’ Health Study, a randomized, double- 
blind, placebo-controlled clinical trial designed to test the 
effect of aspirin on cardiovascular disease and of beta-carotene 
on cancer and cardiovascular disease. Detailed descriptions of 
the methods of the trial have been published elsewhere 
(25,26). Briefly, 21,071 U.S. physicians who were 40 to 84 years 
of age in 1982 and had no previous history of myocardial 
infarction, stroke, cancer, severe debilitating disease, current 
use of aspirin or vitamin A supplements or any ccntraindica- 
tion to the use of aspirin were randomized to take either 
aspirin (325 mg every other day, supplied as Bufferin by 
Bristol-Meyers Products) and beta-carotene (50 mg every 
other day, supplied as Lurotin by BASF), aspirin and beta- 
carotene placebo, beta-carotene and aspirin placebo or both 
placebos. The randomized aspirin arm of the trial was tenni- 
nated early after 5 years of follow-up, principaiiy because of a 
significant beneficial effect of aspirin on the incidence of 
myocardial infarction (25,26), but the beta-carotene compo- 
nent is still ongoing. 
Plasma collection. Before randomization, between August 
1982 and December 1984, all participants were sent kits for 
blood sampling. Participants were instructed to have their 
blood drawn into the provided Vacutainer tubes containing 
EDTA, to centrifuge the blood and to return the plasma in 
polypropylene cryopreservation vials and preserved in cold 
packs (without freezing) by overnight shipment. From August 
1982 through December 1984, a total of 14,916 blood samples 
were received, corresponding to 68% of the trial participants. 
On their arrival at the laboratory. plasma samples were 
refrigerated and realiquoted into six 1.2-ml tubes. Computer- 
printed labels with the identification number only were at- 
tached to the tubes, and they were frozen at -82°C. Through- 
out the period of storage, the samples did not thaw. 
Study design. The present study was designed as a nested 
case-control study based on the cohort of participants in the 
Physician’s Heaith Study who sent a plasma sample before 
randomization (26,27). An incidence-density sampling plan 
within the cohort was implemented (28). At 6-month intervals 
and for each case of myocardial infarction occurring during the 
interval, the blood samples of the case participant and of one 
randomly selected control participant from the set at risk at the 
time the case developed the end point, matched to the case 
participant for age (tl year) and smoking status at caseline 
(current smoker, past smoker or never-smoker), were retrtcved 
and 7naly7ed. Additional information on blood pressure, dia- 
betes and other cardiovascular risk factors was obtained from 
the prerandomization self-administered questionnaire re- 
turned by each participant. The study was approved by the 
Humar~ Research Committee of the Brigham and Women’s 
Hospital. 
End point ascertainment. The case definition was that of 
myocardial infarction (fatal plus nonfatal) adopted in the 
Physicians’ Health Study (25). Specifically, every 6 months for 
the first year and annually thereafter, participants were sent a 
questionnaire to elicit reports of outcomes. Questionnaires of 
deceased participants were usually returned by their families 
or by the postai authority. Those who did not return the 
questionnaires were contacted by totephone. After 5 years, 
morbidity follow-up was 99.7% complete, and mortality 
follow-up was 100% complete. 
For each participant reporting a myocardial infarction or 
for each death, relevant medical records were sought and 
reviewed by an end points committee. Complete medical 
records were obtained for >95% of the reported cases. The 
end points committee, comprising two internists, one cardiol- 
ogist and one neurologist, used the Wcrtd Health Organization 
criteria to confirm a myocardial infarction (29). According to 
these criteria, chest pain and either enzyme elevations or 
characteristic electrocardiographic changes have to be present 
for a positive diagnosis. In particular, silent myocardial infarc- 
tions and sudden unexpected deaths of unknown cause are not 
included in this definition. 
Of 254 cases of myocardial infarction that occurred during 
the initial 5 years of foilow-up among participants with a 
sample of plasma, 32 pairs for cholesterol esters and 41 for 
phospholipids could not be included because there was insuf- 
ficient blood for biochemical analysis in a member of the 
case-control pair. Thus, we included in the analysis 222 case- 
control pairs for cholesterJ esters and ‘213 for phospbolipids. 
Biochemical analyses. The samples of the case participants 
and their corresponding control participants were retrieved 
and thawed in a sonicator. Fatty acid levels were assayed in the 
Lipid Resear& Laboratory at the Brigham and Wnmcn’s 
Hospital. 
Fatty acids in plasma lipcprotein cholesterol esters and 
phospholipids were quantified after plasma extraction with 
hexaneiisopropano! (3:2) (30), separation of the cholesterol 
esters and phospholipids by thin layer chromatography (31) 
and transmethylation in mcthanolic hydrochloride (32). The 
resulting fatty acid methyl es:tirs were quantitated by capillary 
gas chromatography on a 100-m cyanosilicone column (SP2330, 
Supelco) using a temperatme program from 140 to 240°C. A total 
of 56 peaks are reliably identified by pure standards and pub- 
lished retention times, representing >98% of total peak area. 
Retention times used to identify the eicosapentaenoic and doco- 
sahexaenoic peaks were 44.83 and 48.94 mm, respectively. Addi- 
tionally, both peaks were added to form a variable representing 
the total level of ma:ine omega-3 fatty acids in cholesterol esters 
and in phospholiptcis. 
For external quality control, plasma samples from study 
participants were pooled, aliquoted and stored under the same 
conditions as the individuai plasma samples. At least one pair 
of pooled plasma specimens was included for biochemical 
analysis in each batch of 40 samples. The blind-replicate 
coefficients of variation for total levels of fish oils, calculated 
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Table 1. C3mparison of Cardiovascular Risk Factors Between Case 
and Control Participants at Baseline 
MUill 
Value 
for Case 
Participants 
Mean 
h]LC? 
for Control P 
Participanls Value 
EM (kg/m>) 25.1 24.x CO.01 
Systolic BP (mm Hg) 130.4 128.2 0.04 
Diastolic BP (mm Hg) 6i.3 19.5 0,04 
Total cholesterol (mgidl) 221.1 213.9 0.05 
HDL cholesterol (mgidl) 43.6 47.9 co.01 
p values correspond to the paired ditTerences. BMI = body mass index; 
BP = blood pressure; HDL = high density lipoprotein. 
on the basis of the analyses of these samples, were 49.5% and 
21.0% for cholesterol esters and phospholipids, respectively. 
All laboratory procedures were performed in a blinded 
manner with regard to case-control status. Samples for each 
matched pair were treated together and identically and in- 
cluded in the same analytic run from the outset, with the order 
within each pair assigned at random. 
Statistical methods. The relation of fish oil levels with 
baseline risk factors for cardiovascular disease was assessed by 
product-moment correlation coefficients for continuous vari- 
ables or by paired t tests for binary variables. initially, the 
association between fish oil levels and myocardial infarction 
was assessed by paired t tests comparing mean differences 
between case and control samples (33). 
Modeling of the probability of developing a myocardial 
infarction as a function of fish oil levels and of other covariates 
was performed by conditional logistic regression, which pro- 
vides an adequate parametric model for the matched design 
and the incidence density sampling plan used. Under these 
circumstances, the analysis is equivalent to proportional haz- 
ards regression, with the difference that only a randomly 
chosen member of the risk set for a given failure, rather than 
the entire risk set, is used (34). The coefficients in the model 
are interpreted as natural logarithms of the relative risks for 
the corresponding variables, adjusted for other covariates in 
the model. Conditional logistic regression models were fitted 
with Egret, version 0.2501 (35). 
Fish oils were included in the conditional logistic models as 
continuous covariates as well as grouped by quintiles according 
to the distribution of levels in the controls. All p values 
reported are two-tailed. 
Results 
As expected from the matching, case and contra! psrtici- 
pants had a mean age of 58.7 years (SD 8.46), with 17% of both 
reporting smoking at baseline. The levels of other cardiovas- 
cular risk factors for cases and controls at baseline and the 
95% confidence intervals and corresponding p values for the 
paired comparisons are shown in Table 1. As expected, case 
Table 2. Correlation Coefficients Between Plasma Levels of Fish 
Oils and Continuous Cardiovascular Risk Factors at Baseline for 
Case and Control Participants Combined 
Eicosapcntaenoic Docosahexaenoic Both Fish 
Acid Acid Oils 
Cholesterol rsters 
A@ 0.04 0.04 0.05 
BMI 0.09 0.02 0.06 
Systolic BP 0.05 -0.03 0.00 
Diastolic BP 0.08 -0.01 0.04 
Total cholesterol 0.04 -0.02 0.00 
HDL cholesterol 0.01 0.08 0.06 
Phospholipids 
Age 0.04 0.07 0.07 
BMi 0.08 0.04 0.06 
Systolic BP 0.12’ 0.07 0.10* 
Diastolic BP 0.13* 0.09 0.11% 
Total cholesterol 0.05 0.02 0.03 
HDL cholesterol 0.06 0.02 0.02 
-w-m- 
*p i 0.05. Abbreviations as in Table 1. 
participants had significantly higher levels of body mass index, 
systolic and diastolic blood pressures and total cholesterol and 
lower levels of high density lipoprotein (HDL) cholesterol. 
The product-moment correlation coefficients between eico- 
sapentaenoic acid and docosaheaenoic acid, and their combi- 
nation, with body mass index, systolic and diastolic blood 
pressures and total and HDL cholesterol levels at baseline for 
the combined sanrpie of case and control participants are 
shown in Table 2 for both cholesterol esters and phospholipids. 
The magnitude of each of these coeihcients was small, and a 
positive correlation is significant for blood pressure and eico- 
sapentaenoic acid only (r = 0.12 for systolic blood pressure and 
I = 0.13 for diastolic blood pressure) and for blood pressure 
and the sum of both fish oil levels (r = 0.10 for systolic blood 
pressure and r = 0.11 for diastolic blood pressure) in phos- 
pholipids. Fish oil levels were similar between diabetic and 
nondiabetic participants and between those with and without 
angina (data not shown). 
Eicosapentaenoic and docosahexaenoic acids were moder- 
ately correlated with one another (r = 0.33 [p < O.OOl] in 
cholesterol esters; r = 0.45 [p < O.OOl] in phospholipids). The 
correlation between omega-3 fatty acids in cholesterol esters 
and phospholipids was r = 0.35 (p < 0.001) for eicosapentae- 
noic acid, r = 0.06 (p 2 0.21) for dvcosanexaenoic acid, and 
r = 0.19 (p < 0.001) for the combination of bth fish oils. 
Mean levels of eicosapentaenoic and docosahexaenoic acids 
and their combination in cholesterol esters and phosphohpids 
at baseline for case and control participants are shown in Table 
3. Case participants had levels very similar to those of their 
matched control participants, and none of the differences were 
significant. 
The conditional logistic regression coefficients for the levels 
of fish oils considered as c\rrninuous variables, adjusted for 
body mass index, history of diabetes, angina, blood pressure, 
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‘&fble 3. Comparison of Fish Oil Peak Values a: Baseline Between 
Case and Control Participants 
Mean Mean 
Value for Value for 
Case Control 
Participants Participants P 
(SD) WY 95% CI Value 
Chole.terol esters 
Eicosapentaenoic 0.26 0.25 -0.03-0.05 0.70 
acid (0.22) (0.22) 
Docosahexaenoic 0.23 0.24 -0.07-0.04 0.64 
acid (0.28) (0.34) 
Both fish oils 0.49 0.49 -0.08-0.07 0.8S 
(0.40) (0.47) 
Pnospholipids 
Eicosaperltaeno,L 0.56 0.54 -0.04-0.09 0.44 
acid (0.35) (0.36) 
Docosahexaenoic 2.22 2.14 4’ IO--O.27 0.36 
acid (1.05) (1.02) 
Both fish oils 2.79 1.68 .I. - 0.33 0.32 
(1.23) (1.25) 
Fish oils are given as percent of total fatty acid peak area. The 95% 
confidence intervals (CI) and p values reported correspond to the paired 
randomized treatment assignment and levels of total and HDL 
cholesterol, are shown in Table 4. Further adjustment for 
levels of pahnitic, stearic, oleic, linoleic, linolenic and arachi- 
donic acids did not materially affect the conclusions (data not 
shown). The magnitude of these coefficients must be inter- 
preted with respect to the magnitude of the individual fatty 
acid peak areas. For instance, an average increase of 0.5% U in 
peak area would represent an 89% increase in eicosapentae- 
noic acid peak area in phospholipids but a 22% increase in 
docusahexaenoic acid in phospholipids. To obtain estimates of 
relative risk that could be compared in terms of proportional 
increase in each fatty acid peak area, we used the logistic 
regression model to calculate ihe corresponding estimated risk 
ratios associated with a 50% increase in fatty acid peak area 
and their 95% confidence intetva!s. For eicosapentaenoic acid 
and docosahexaenoic acid, and their combination, they were 
1.05 (95% CI 0.91 to 1.21), 1.02 (95% CI 0.94 to 1.11) and 1.05 
(95% CI 0.92 to 1.19) in cholesterol esters and 1.01 (95% CI 
0.84 to 1.2!), 1.06 (95% CI 0.81 to 1.39) and 1.06 (95% CI 0.80 
to 1.40) in phospholipids. For a 50% increase in total omega-3 
fatty acid area, the power of the study to detect a 25% 
reduction in the incidence of myocardial infarction was >99% 
in chde%rd esters and 67% in phospholipids, and the power 
to detect a SO?0 reduction in risk was >99% in both classes of 
lipids. 
Tabfc 5 prcscnts the risk ratios for the conditiona! logistic 
regression of fish oil levels categorized by quintiles, adjusted 
for other cardiovascular risk factors. None of the reported p 
values for linear trend across the quintiles was signiticant, 
indicating no evidence for a linear component in a dose- 
response model. As in the analysis with fish oils considered as 
Table 4. Adjusted Results of Conditional Logistic Regression 
Models for EEect of Fish Oil Levels on Incidence of 
Myocardial Infarction* 
Standard 
Error Relative 
of P Riski: 
Coefficient? Coefficient Value (95% CI) 
Cholesterol esters 
Eicosapentaenoic 
acid 
Docosahexaenoic 
acid 
Both fish oils 
Phospholipids 
Xicosapentaenoic 
acid 
Docosahexaenoic 
acid 
Both fish oils 
0.363 0.587 0.54 1.05 
(0.91-1.21) 
0.192 0.354 0.59 1.02 
(0.94-1.11) 
0.180 0.263 0.50 1.05 
(0.92-1.19) 
0.033 0.350 0.92 1.01 
(0.84-1.21) 
0.057 0.130 0.66 1.06 
(0.81-1.39) 
o.u42 0.107 0.70 1.06 
(0.80-1.40) 
In these models, fish oil levels are considered continuous variables measured 
in percentage points of total fatty acid peak area. *Results adjusted for body 
mass index. history of diabetes, angina. blood pressure. randomized treatment 
assignment and total and HDZ cholesterol levels. +To calculate the relativle risk 
associated kirh an increase in x percentage point units of fatty acid peak area for 
a particular fish oil. use the formula RR = excoea’c’en’ (e.g., the relative risk 
associated with an increase of 0.2 percentat; point units in docosdhexaenoic acid 
in cholesterol esters is e” a’( -‘I w = 0.97). $Relative risk and 95% confidence 
interval (CI) associated with a 51;% increase in the corresponding fish oil peak 
level. 
continuous variables, further adjustment for levels of major 
fatty acids did not alter the estimates appreciably. 
Despite a lack of association between fish oil levels and 
myocardial infarction, we evaluated whether there was effect 
modification by other cardiovascular risk factors. To do so. we 
evaluated the interaction term (the product of the cardiovas- 
cular risk factor and the specific fish oil) in conditional logistic 
regression models (with omega-3 fatty acids as continuous 
variables). None of the interactions between the fish oil levels 
and the cardiovascular risk factors studied, including those for 
age, smoking, systolic and diastolic blood pressures and total 
and HDL cholesterol levels, was statistically significant. Be- 
cause aspirin reduced the risk of myocardisl infarction in the 
trial by 44%, the possibility of interaction between fish oils and 
random assignment to aspirin was of particular relevance. The 
p values for the interaction terms between assignment to 
aspirin in the trial and eicosapentaenoic and docosahexaenoic 
acids and their sum considered as continuous variables were 
0.22,0.90 and 0.32 for cholesterol esiers and 0.52,0.38 and 0.35 
for pbosphoiipids, respectively. To explore further the joint 
effect of aspirin and fish oils, we categorized fish oil levels in 
two groups, below and above the median of the corresponding 
fish oil in the control participants. Unadjusted relative risk 
estimates for each combination of assignment to aspirin (yes or 
no) and fish oil levels (above or below median) are shown in 
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Table 5. Adjusted Relative Risk Estimates (and 95% confidence intervals) From Conditional Lo&tic 
Regression Model for Effect of Fish Oil Levels on Incidence of Myocardial Infarction, With Fish Oil 
Levels Categorized by Quintilrr* 
l__l___~ 
P 
Value 
Quintile 1 Quintile 2 Quintile ? Quintk 4 Quintile 5 Trend 
Cholesterol esters 
Eicosapep!aenoic acid 
Median iwelt 
Relative risk 
95% Cl 
Docosahexacnoic acid 
Median level% 
Relative risk 
95% CI 
Both fish oils 
Median leveli 
Relative risk 
95% CI 
Phospholipids 
Eicosapentaenoic acid 
Median levelt 
Relative risk 
95% cr 
Docosahexaenoic acid 
M~~%n level* 
Rel,!!tive risk 
95% Cl 
Both fish oils 
Median leveli 
Relative risk 
95% Cl 
0.05 0.12 0.20 0.30 0.52 
1.00 1.37 1.68 0.96 1.79 
Reference 0.68-3.04 0.75-3.17 0.43-2.14 0.83-3.90 
0.00 
l.oil 
Reference 
0.11 0.18 0.25 0.43 
1.14 1.48 1.09 1.68 
0.50-2.61 0.67-3.28 0.45-2.66 0.X-3.74 
0.12 0.23 0.39 0.55 0.94 
I .bJ 1.16 i .2i i.05 1.96 
Reference 0.51-2.60 ll.50-2.94 0.47-2.34 0.87-4.41 
0.24 0.38 0.49 0.61 0.90 
1.00 0.93 0.55 0.67 1.11 
Reference 0.44-1.98 0.X-l .23 0.3i-1.45 0.S2.35 
! .n2 1.69 2.11 2.49 3.43 
1.00 1.23 0.81 1.06 1.26 
Reference 0.52-2.90 0.35-1.87 0.50-2.28 0.54-2.9! 
1.37 2.12 2.58 3.00 4.33 
1.00 1.62 0.61 1.52 1.55 
Reference 0.65-4.02 0.25-1.52 0.69-3.31 0.67-3.54 
0.26 
0.19 
0.11 
0.75 
0.64 
0.30 
*Results adjusted for body mass index. history of diabetes. angina, blood pressure. randomized treatment assignment 
and total and HDL cholesterol levels. iMedian level for the quintile of the corresprnding fish oil, expressed as percent 
of total fatty acid peak area. CI = confidence interval. 
Table 6 (results were similar after adjustment for cardiovascu- 
lar risk factors). Fish oil levels did not modify the benefit of 
aspirin on the incidence of myocardial infarction. Further- 
more, there is no evidence for a protective effect of increased 
fish oil levels among tiiose assigned to the no-aspirin arm of the 
trial. 
IXscussion 
Strengths and limitations of present study. After 5 years of 
follow-up, increased levels of fish oils in plasma lipids, either 
analyzed as continuous variables or #categorized in quintiles, 
conferred no significant reduction of the risk of myocardial 
infarction. Furthermore, for most of the estimates, the 95% 
confidence intervals were reasonably narrow, suggesting that 
even a substantial increase in plasma fish oil levels could have 
at most only a small benefit. Similarly, analysis of fish intake 
based on reported dietary data in the same cohort showed no 
association between fish consumption and risk of cardiovascu- 
lar disease (36). 
It is possible that the physicians at higher risk of myocardial 
infarction were more likely to be aware of the possible benefits 
of fish oils and may have modified their fish or fish oil intake 
differently than those who considered themselves at lower risk. 
If fish oils had a beneficial effect, selective increased intake of 
fish or use of fish oil suppiements among those at higher risk 
would bias estimates of relative tisk associated with fish oil 
intake idwar? ,‘- e null. In our study, we used two strategies to 
control for titl~r risk factors for cardiovascular disease. First, 
we us * -#, ,,ed design in which the control participant fcr 
each case p.. -ticipant was restricted to the same age (21 year) 
and the same smoking category (current, past or never) as the 
corresponding case participant. Second, we used conditional 
logistic regression to adjust for other levels of important 
cardiovascular risk factors, including blood pressure, total and 
HDL cholesterol and presence of diabetes. The correlation 
between plasma levels of fish oils in cholesterol esters and 
phospholipids and these risk factors at baseline was very small, 
suggesting that such self-selecticn by risk factor status did not 
OCCW. 
An additional limitation of this study is the precision of the 
chromatagraphic determinations of the marine omega-3 fatty 
acids, as reflected in the relatively high coefficients of variation 
for blind-replicate analysis of pooled plasma sample from the 
392 GUALLAR ET AL. JACC Vol. 25, No. 2 
FISH OILS AND RISK OF MYOCARDIAL INFARC?JON February 19953337-94 
Tattle 6. Relative Risk Estimates for the Effect of Aspirin and Fish Oil Levels on Incidence of 
Myocardial Infarction 
Fish Oil Levels Below Fish Oil Levels Above 
Median Median 
No No p Value 
Aspirin Aspirin Aspirin Aspirin Interaction 
Cholesterol esters 
Eicosapentaenoic acid 1.00 0.62 0.95 0.65 0.79 
Docotahexeenoic acid 1.00 0.65 I.12 0.73 0.99 
Both iish oils 1.00 0.54 0.99 0.74 0.41 
Phospholipids 
Eicosapentaenoic acid 1.00 0.67 1.81 1.23 0.98 
Docosahexaenoic acid 1.00 0.62 1.25 0.84 0.95 
Both fish oils 1.00 0.82 2.15 1.44 0.90 
The groups with fish oil levels below and above the median are defined with respect to the corresponding fish oil in 
the ,-ontrol group. Estimates are from conditional logistic regression models. 
study participants. These are small peaks on the chromato- 
gram, typically constituting ~0.5% of total fatty acid peak area 
in cholesterol esters and <3% in phospholipids because of the 
higher afinity of polyunsaturated omega-3 fatty acids for 
phospholipids (9). Nonetheless, there is no suggestion of a 
trend toward lower risk among those with higher levels of fish 
oils; in fact, the trend (nonsignificant) is in the opposite 
direction. 
Comparison with results from other studies. Compared 
with results from dose-response trials of fish or fish oil 
supplements (9,37--4O), the levels of eicosapentaenoic acid in 
cholesterol esters and phospholipids in our study were even 
lower than those rypically resulting from the lowest interven- 
tion doses in these trials (usually 1.5 g of fish oil/day, corre- 
sponding roughly tc two servings of 300 g of fatty fish/week). 
Although we cannot derive a precise estimate, the average 
intake of fish or fish oils in the preseiit study was probably 
comparable to the estimated intake of -150 mg of omega-3 
fatty acids/day for the U.S. population based on foods available 
for consumption in the national food supply (10). Similar 
intakes have been found in other large-scale studies in the 
United States (24). Therefore, although confounding effects 
cannot be excluded, it seems unlikely that preventive intake of 
fish oils wap not widespread enough to materially affect the 
results. 
In the Zutphen study (IS), 872 men who had completed a 
dietary history in 1960 were foliowed for an average of LO years 
(78 died of coronary causes). In that study, a 40% reduction in 
the risk of death from coronary heart disease was found even 
in those participants who ate only 1 to 14 g of fish/day 
compared with those who did not eat fish. However, in the 
Zutphen cohort, intake of lean fish was also inversely related to 
coronary heart disease mortality, and the marked decrease in 
cardiovascular risk was associated with levels of fish intake 
lower than those required to show a physiologic effect of fish 
oils on blood pressure or lipid levels. 
Fish intake also was associated with reduced coronary heart 
disease murtality in two additional cohort studies. In the 
Western Electric Study (19) 1,931 men were followed for an 
average of 25 years. In this study, the estimated risk reduction 
was less than that in the Zutphen study (men eating 1 to 17 g 
of fish had a 19% lower risk than those who ate no fish), 
although a dose-response relation between fish intake and 
coronary mortality was present. Similar results were found 
among 6,258 participants in the usual-care group of the 
Multiple Risk Factor Intervention Trial (24). After 7.5 years 01 
follow-up, the relative risks for quintiles of omega-3 fatty acid 
intake two through five compared with the quintile one were 
1.01, 0.87, 0.87 and 0.59. 
Other prospective observational studies of fish intake have 
shown no beneficial effects. In a cohort in Norway, 11,000 men 
were followed for an average of 14 years (20). The estimated 
risk ratios of coronary heart disease mortality for the catego- 
ries of 5 to 9, 10 to 14, I5 to 19, 20 to 24 and 225 servings of 
fish eaten/month, compared to 0 to 4 servings eaten/month, 
were 1.24, 1.10, 1.10, 1.23 and 1.06, respectively (p = 0.93 for 
the test of trend). Similarly, in a cohort of 10,966 Swedish men 
and women followed for 14 years (22), the relative risk 
estimates for the categories of moderate and high fish intake, 
compared with low fish intake, were 0.94 and 0.85 (neither 
achieved statistical significance). The 1Zyear follow-up study 
of 7,616 Japanese men in the Honolulu Heart Program (21) 
showed no consistent effect of fish intake. The relative risks for 
those consuming 1 to 2,3 to 4,5 to 6 and >6 oz (28 to 56,84 
to 112, 140 to 168 and >168 g) of fish/day compared to those 
with no intake of fish were 0.69, 1.11, 0.84 and 0.92, respec- 
tively, with a nonsignificant test for trend. Finally, in the report 
(23) of a study of dietary habits in relation to incidence of 
cardiovascular disease in 1,462 women in Sweden, there was no 
relation between fish intake and cardiovascular disease. 
In contrast to previous studies, we used plasma levels of 
omega-3 fatty acids as %!ngic markers for fish intake. This is 
justified by the almost linea: reiation b&veen intake of fish or 
fish oil supplements and plasma levels of eicosapentaenoic and 
docosahexaenoic acids over a range of doses (37-40). How- 
ever, omega-3 fatty acids are not the only components of fish. 
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In fact, the possible effect of other constituents of fish has been 
proposed as an explanation of the inverse association between 
intake of lean fish and coronary mortality among the partlci- 
pants in the Zutphen study (18). Although the number of 
published studies is too small to permit a systematic study, 
differences in design, including end point definition, length of 
follow-up and level of fish intake in the participants, do not 
seem to explain the different results. 
In a randomized controlled trial, 2,1l33 men with a previous 
myocardial infarction were randomized using a factorial design 
to receive advice or no advice on each one of three interven- 
tions: reduction in fat intake and increase in the polyunsaturated/ 
saturated fat ratio, increase in fatty fish intake and increase in 
intake of cereal fiber (17). The intervention for the fish advice 
group consisted of recommending to the participants the 
intake of at least two weekly portions (200 to 400 g) of fatty 
fish. After 2 years of follow-up, with 224 deaths from all causes, 
the fish advice group showed a 29% reduction in total mortality 
and a 16% reduction in ischemic heart disease events. The 
differences in mortality between the two groups appeared very 
early in the trial and were maintained throughout the 
follow-up period. 
Conclusions. The only clinical trial of fish intake in patients 
with preexisting coronary heart disease sr!pports the hypothesis 
of a protective effect of fish intake on cardiovascular mortality. 
However, the conflicting results of observational cohort studies 
require further clarification. Because of the large number of 
cohort studies with dietary information already collected and 
processed, further insight into this issue could be gained from 
existing data. However, our results, based on plasma levels of 
fish oils rather than on nutrient intake data in a population 
with a relatively low fish intake: do not support the hypothesis 
of a beneficial effect of increased fish oil levels in plasma on the 
incidence of a first myocardial infarction in mpn. 
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